Diabetes in developing countries.

Anoop Misra, Hema Gopalan, Ranil Jayawardena, Andrew P Hills, Mario Soares, Alfredo A Reza-Albarrán, Kaushik L Ramaiya

Journal: Journal of diabetes 2019;11(7):522-539

PMID: 30864190

Abstract

There has been a rapid escalation of type 2 diabetes (T2D) in developing countries, with varied prevalence according to rural vs urban habitat and degree of urbanization. Some ethnic groups (eg, South Asians, other Asians, and Africans), develop diabetes a decade earlier and at a lower body mass index than Whites, have prominent abdominal obesity, and accelerated the conversion from prediabetes to diabetes. The burden of complications, both macro- and microvascular, is substantial, but also varies according to populations. The syndemics of diabetes with HIV or tuberculosis are prevalent in many developing countries and predispose to each other. Screening for diabetes in large populations living in diverse habitats may not be cost-effective, but targeted high-risk screening may have a place. The cost of diagnostic tests and scarcity of health manpower pose substantial hurdles in the diagnosis and monitoring of patients. Efforts for prevention remain rudimentary in most developing countries. The quality of care is largely poor; hence, a substantial number of patients do not achieve treatment goals. This is further amplified by a delay in seeking treatment, "fatalistic attitudes", high cost and non-availability of drugs and insulins. To counter these numerous challenges, a renewed political commitment and mandate for health promotion and disease prevention are urgently needed. Several low-cost innovative approaches have been trialed with encouraging outcomes, including training and deployment of non-medical allied health professionals and the use of mobile phones and telemedicine to deliver simple health messages for the prevention and management of T2D.

© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Address: National-Diabetes, Obesity and Cholesterol Foundation, Safdarjung Development Area, New Delhi, India.; Diabetes Foundation (India), New Delhi, India.; Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India.; National-Diabetes, Obesity and Cholesterol Foundation, Safdarjung Development Area, New Delhi, India.; Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.; School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania, Australia.; School of Public Health, Curtin University, Perth, Western Australia, Australia.; Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Shree Hindu Mandal Hospital, Tanzania.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.